Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

Lancet
P M KearneyC Baigent

Abstract

Although statin therapy reduces the risk of occlusive vascular events in people with diabetes mellitus, there is uncertainty about the effects on particular outcomes and whether such effects depend on the type of diabetes, lipid profile, or other factors. We undertook a prospective meta-analysis to help resolve these uncertainties. We analysed data from 18 686 individuals with diabetes (1466 with type 1 and 17,220 with type 2) in the context of a further 71,370 without diabetes in 14 randomised trials of statin therapy. Weighted estimates were obtained of effects on clinical outcomes per 1.0 mmol/L reduction in LDL cholesterol. During a mean follow-up of 4.3 years, there were 3247 major vascular events in people with diabetes. There was a 9% proportional reduction in all-cause mortality per mmol/L reduction in LDL cholesterol in participants with diabetes (rate ratio [RR] 0.91, 99% CI 0.82-1.01; p=0.02), which was similar to the 13% reduction in those without diabetes (0.87, 0.82-0.92; p<0.0001). This finding reflected a significant reduction in vascular mortality (0.87, 0.76-1.00; p=0.008) and no effect on non-vascular mortality (0.97, 0.82-1.16; p=0.7) in participants with diabetes. There was a significant 21% proportional re...Continue Reading

References

Apr 1, 1987·Diabetes/metabolism Reviews·K PyöräläM Uusitupa
Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Jun 22, 2002·JAMA : the Journal of the American Medical Association·Patrick W J C SerruysUNKNOWN Lescol Intervention Prevention Study (LIPS) Investigators
Sep 12, 2002·Acta Diabetologica·M R Taskinen
Nov 30, 2002·Lancet·James ShepherdUNKNOWN PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk
Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm
Jun 20, 2003·Lancet·Hallvard HoldaasUNKNOWN Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators
Nov 9, 2004·Atherosclerosis. Supplements·T R PedersenUNKNOWN Scandinavian Simvastatin Survival Study Group
Dec 21, 2005·Heart·UNKNOWN British Cardiac SocietyUNKNOWN Stroke Association
Aug 11, 2006·The New England Journal of Medicine·Pierre AmarencoUNKNOWN Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators
Dec 29, 2006·Diabetes Care·UNKNOWN American Diabetes Association
Jan 24, 2007·Lancet·J Abramson, J M Wright
Mar 3, 2007·Clinical Chemistry·Andrew S LeveyUNKNOWN Chronic Kidney Disease Epidemiology Collaboration

❮ Previous
Next ❯

Citations

Apr 25, 2012·Diabetologia·P T Sawicki
Jul 25, 2009·European Journal of Clinical Pharmacology·Maarit Jaana KorhonenArja Helin-Salmivaara
Feb 15, 2013·European Journal of Clinical Pharmacology·Christina L AquilanteJulie A Predhomme
Mar 17, 2010·Wiener medizinische Wochenschrift·Christoph H Saely, Heinz Drexel
Jul 20, 2011·Wiener medizinische Wochenschrift·Bernhard Föger
Jan 23, 2009·Cardiovascular Drugs and Therapy·Sergio Fazio
Mar 12, 2010·Reviews in Endocrine & Metabolic Disorders·Fredrick L Dunn
Feb 12, 2013·Reviews in Endocrine & Metabolic Disorders·Kieren J Mather
Jul 3, 2013·Journal of General Internal Medicine·Varsha G VimalanandaEve A Kerr
Nov 2, 2011·Internal and Emergency Medicine·Alberto Zambon
Dec 17, 2008·Current Atherosclerosis Reports·Peter Baginsky
Jun 9, 2009·Current Atherosclerosis Reports·Catherine Fiévet, Bart Staels
Apr 29, 2010·Current Atherosclerosis Reports·Michael Clearfield
Dec 29, 2011·Current Atherosclerosis Reports·Jamal S RanaPrediman K Shah
Jan 10, 2013·Current Atherosclerosis Reports·Patricia RehfieldMichael Clearfield
Jun 10, 2010·Current Diabetes Reports·Ishwarlal JialalManpreet Kaur
Mar 9, 2012·Current Diabetes Reports·Lewis H Kuller
Apr 3, 2012·Current Diabetes Reports·Preeti KishoreJill P Crandall
Mar 13, 2013·Drugs·Joe M ChehadeArshag D Mooradian
Feb 21, 2009·Nature Clinical Practice. Endocrinology & Metabolism·Arshag D Mooradian
May 1, 2009·Nature Reviews. Drug Discovery·Nigel A CalcuttAnn Marie Schmidt
Oct 5, 2011·Seminars in Reproductive Medicine·Melissa Wellons
Nov 3, 2010·Metabolic Syndrome and Related Disorders·Om P Ganda
Mar 10, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Seung Hyeok HanShin-Wook Kang
Sep 17, 2011·QJM : Monthly Journal of the Association of Physicians·M AlbertonE J Mills
Jul 4, 2012·QJM : Monthly Journal of the Association of Physicians·S H Song, T A Gray
Nov 26, 2008·JAAPA : Official Journal of the American Academy of Physician Assistants·Kenneth E Korber
Apr 19, 2011·Current Opinion in Cardiology·Uchechukwu K SampsonSergio Fazio
Jun 26, 2010·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Kornelia KotsevaUNKNOWN EUROASPIRE Study Group
Oct 30, 2008·Current Opinion in Lipidology·D John Betteridge

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.